首页524816 • BOM
add
纳特科制药
昨日收盘价
₹1,389.35
当日价格范围
₹1,364.80 - ₹1,403.00
年度波幅
₹725.00 - ₹1,638.35
市值
2505.75亿 INR
平均交易量
5.38万
市盈率
15.33
股息率
0.39%
主要交易所
NSE
市场资讯
财务信息
损益表
收入
净收入
(INR) | 2024年6月info | 年同比变化 |
---|---|---|
收入 | 136.26亿 | 19.47% |
经营支出 | 42.17亿 | 3.11% |
净收入 | 66.85亿 | 59.05% |
净利润率 | 49.06 | 33.13% |
每股收益 | 37.32 | 60.45% |
息税折旧摊销前利润 | 80.74亿 | 40.06% |
有效税率 | 16.81% | — |
资产负债表
总资产
负债总额
(INR) | 2024年6月info | 年同比变化 |
---|---|---|
现金及短期投资 | 184.92亿 | 59.13% |
总资产 | — | — |
负债总额 | — | — |
权益总额 | 585.31亿 | — |
发行在外的股份 | 1.79亿 | — |
市净率 | 4.25 | — |
资产回报率 | — | — |
资本回报率 | 30.55% | — |
现金流
现金净变动
(INR) | 2024年6月info | 年同比变化 |
---|---|---|
净收入 | 66.85亿 | 59.05% |
来自运营的现金 | — | — |
投资现金 | — | — |
融资现金 | — | — |
现金净变动 | — | — |
自由现金流 | — | — |
简介
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad with a presence in formulation and active pharmaceutical ingredients in both domestic and international markets. The company also manufactures Agro chemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs. The company specialises in producing complex medicines at affordable prices. The company has a presence in 50+ countries. NATCO is a science driven company and focuses on limited competition molecules in the US .The company’s pharma division has 5 manufacturing facilities, 2 API and intermediate manufacturing facilities and the crop health sciences division has one formulation and one technical manufacturing facility. The company boasts of having a talent pool of 450+ scientists working out of two research centers in India.
Across the globe, cancer treatment saw a sea change in early 2000s in terms of screening, diagnosis, molecular pathology, targeted therapies, immunotherapies, Bone Marrow Transplants, and supportive care. Wikipedia
CEO
成立时间
1981
员工数量
4,016